Pharmacological Hypogonadotropism Can be Used to Advantage for Ovulation Induction Protocols

  • G. Bettendorf
  • W. Braendle
  • Ch. Lindner
  • V. Lichtenberg
  • M. Luckhardt
  • T. Schlotfeld

Abstract

Ovarian stimulation with hMG/hCG is an established therapeutic principle in anovulatory patients with amenorrhea, low gonadotropins and a negligible endogenous estrogen production. Exogenous gonadotropins are also used for ovarian stimulation in women who are not typical candidates for this type of treatment, i.e. those with anovulatory cycles and in cases of luteal insufficiency which do not respond to clomiphene. In addition, exogenous gonadotropins are given to patients who are to be prepared for intrauterine insemination, in vitro fertilization (IVF) or gamete intrafallopian transfer (GIFT) in order to achieve multifollicular development.

Keywords

Ovarian Stimulation Ovarian Hyperstimulation Syndrome Early Follicular Phase Intrauterine Insemination Exogenous Gonadotropin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bettendorf, G and Breckwoldt, M (1964). Klinisch-experimentelle Untersuchungen mit hypophysaerem Human-Gonadotropin. Archiv fuer Gynaekologie, 199, 423CrossRefGoogle Scholar
  2. 2.
    Bettendorf, G, Braendle, W, Sprotte, Ch, Poels, W, Lichtenberg, V and Lindner, Ch (1986). Pharmacologic hypogonadotropism — an advantage for hMG-induced fol1icular-maturation and succeeding fertilization. Horm Metab Res, 18, 656PubMedCrossRefGoogle Scholar
  3. 3.
    Diczfalusy, E, Johannisson, E, Tillinger, KG and Bettendorf, G (1964). Comparison of the clinical and steroid metabolic effect of human pituitary and urinary gonadotropins in amenorrhoeic women. Acta Endocrinol, 45 (Suppl. 90), 35PubMedGoogle Scholar
  4. 4.
    Bettendorf, G, Braendle, W, Weise, C, Poels, W (1981). Effect of gonadotropin treatment during inhibited pituitary function. In: Insler V and Bettendorf, G (eds.) “Advances in diagnosis and treatment of infertility”, p.43 (North Holland: Elsevier)Google Scholar
  5. 5.
    Bettendorf, G, Braendle, W and Sprotte C (1985). Gonadotropin-Stimulation waehrend einer LH/RH-Analogon-induzierten Hemmung der Hypophysenfunktion. Geburstsh u Frauenheilk, 45, 431CrossRefGoogle Scholar
  6. 6.
    Lindner, Ch, Braendle, W, Bispink, L, Lichtenberg, V and Bettendorf, G (1987). Gonadotropin-Stimulation und in-vitro-Fertilisation nach selektiver Hypophysen-Suppression durch LH/RH-Analogon. Geburtsch u Frauenheilk, 47, 490CrossRefGoogle Scholar
  7. 7.
    Lindner, Ch, Braendle, W, Bispink, L, Lichenberg, V and Bettendorf, G (1987). HMG-induced follicular maturation after blocking of endogenous pituitary gonadotropin discharge. Acta Endocrinol (Copenh.), 283 (Suppl. 114), 169Google Scholar
  8. 8.
    Zimmermann, R, Soor, B, Braendle, W, Lehmann, F, Weise, HC and Bettendorf, G (1982). Gonadotropin therapy of female infertility. Gynecol Obstet Invest, 14, 1PubMedCrossRefGoogle Scholar
  9. 9.
    Rabau, E, David, A, Serr, DM, Mashiach, S and Lunenfeld, B (1967). Human menopausal gonadotropins for anovulation and sterility. Am J Obstet Gynecol, 98, 92PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • G. Bettendorf
    • 1
  • W. Braendle
    • 1
  • Ch. Lindner
    • 1
  • V. Lichtenberg
    • 1
  • M. Luckhardt
    • 1
  • T. Schlotfeld
    • 1
  1. 1.Abteilung fuer klinische und experimentelle Endokrinologie der Universitaets-Frauenklinik2000 Hamburg 20Germany

Personalised recommendations